Online citations, reference lists, and bibliographies.
← Back to Search

Modulation Of Anxiety Through Blockade Of Anandamide Hydrolysis

S. Kathuria, S. Gaetani, D. Fegley, F. Valiño, A. Duranti, A. Tontini, M. Mor, G. Tarzia, G. L. Rana, A. Calignano, A. Giustino, M. Tattoli, M. Palmery, V. Cuomo, D. Piomelli
Published 2003 · Medicine
Referenced 1 time by Citationsy Users

Save to my Library
Download PDF
Analyze on Scholarcy
The psychoactive constituent of cannabis, Δ9-tetrahydrocannabinol, produces in humans subjective responses mediated by CB1 cannabinoid receptors, indicating that endogenous cannabinoids may contribute to the control of emotion. But the variable effects of Δ9-tetrahydrocannabinol obscure the interpretation of these results and limit the therapeutic potential of direct cannabinoid agonists. An alternative approach may be to develop drugs that amplify the effects of endogenous cannabinoids by preventing their inactivation. Here we describe a class of potent, selective and systemically active inhibitors of fatty acid amide hydrolase, the enzyme responsible for the degradation of the endogenous cannabinoid anandamide. Like clinically used anti-anxiety drugs, in rats the inhibitors exhibit benzodiazepine-like properties in the elevated zero-maze test and suppress isolation-induced vocalizations. These effects are accompanied by augmented brain levels of anandamide and are prevented by CB1 receptor blockade. Our results indicate that anandamide participates in the modulation of emotional states and point to fatty acid amide hydrolase inhibition as an innovative approach to anti-anxiety therapy.
This paper references
Behavioral effects of cannabinoid agents in animals.
F. Chaperon (1999)
WAY 100135, an Antagonist of 5-HT1A Serotonin Receptors, Attenuates Psychotomimetic Effects of MK-801
Krzysztof Wdzony (2000)
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor.
D. Deutsch (1997)
A second endogenous cannabinoid that modulates long-term potentiation
N. Stella (1997)
Major biological actions of CCK – a critical evaluation of research findings
H. Fink (1998)
Cannabinoids: a real prospect for pain relief?
L. Iversen (2002)
Brain monoglyceride lipase participating in endocannabinoid inactivation
T. V. Dinh (2002)
Functional role of high-affinity anandamide transport, as revealed by selective inhibition.
M. Beltramo (1997)
Ultrasonic vocalization in rat pups: Effects of early postnatal exposure to SCH 23390 (a DA1-receptor antagonist) and sulpiride (a DA2-receptor antagonist)
V. Cuomo (1987)
Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety
J. K. Shepherd (2005)
Localization of the CB 1 type cannabinoid receptor in the rat basolateral amygdala : high concentrations in a subpopulation of cholecystokinincontaining interneurons
A. J. McDonald (2001)
Locomotor and learning deficits in adult rats exposed to monosodium-l-glutamate during early life
M. M. Ali (2000)
Control of pain initiation by endogenous cannabinoids
A. Calignano (1998)
Mechanisms of emotional arousal and lasting declarative memory
L. Cahill (1998)
Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase.
L. De Petrocellis (1997)
Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry.
A. Giuffrida (2000)
Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide.
D. Boger (2000)
high concentrations in a subpopulation of cholecystokinincontaining interneurons
A. J. McDonald (2001)
Involvement of CB1 cannabinoid receptors in emotional behaviour
M. Martin (2001)
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.
R. Mechoulam (1995)
a real prospect for pain relief? Curr
L. Iversen (2002)
GABAA and 5-HT anxiolytics
K. A. Miczek (1995)
Distribution of CB1 Cannabinoid Receptors in the Amygdala and their Role in the Control of GABAergic Transmission
I. Katona (2001)
Adverse effects of cannabis
W. Hall (1998)
Receptor-dependent formation of endogenous cannabinoids in cortical neurons.
N. Stella (2001)
Inhibition of anandamide hydrolysis in rat brain tissue by (E)‐6‐(bromomethylene) tetrahydro‐3‐(1‐naphthalenyl)‐2H‐pyran‐2‐one
M. Beltramo (1997)
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
W. Devane (1992)
Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolases with distinct catalytic properties.
M. Patricelli (1999)
Formation and inactivation of endogenous cannabinoid anandamide in central neurons
V. Marzo (1994)
Activation of CB1 cannabinoid receptors in rat hippocampal slices inhibits potassium-evoked cholecystokinin release, a possible mechanism contributing to the spatial memory defects produced by cannabinoids
M. Beinfeld (2001)
Aggression, anxiety and vocalizations in animals: GABAA and 5-HT anxiolytics
K. Miczek (2005)
An anorexic lipid mediator regulated by feeding
F. D. Fonseca (2001)
Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
M. Glass (1997)
Infant rat separation is a sensitive test for novel anxiolytics
J. Winslow (1991)
The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety
J. Haller (2002)
a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain
M. Glass (1997)
Cannabinoid receptor localization in brain.
M. Herkenham (1990)
Inhibitors of arachidonoyl ethanolamide hydrolysis.
B. Koutek (1994)
Cannabinoid effects on anxiety-related behaviours and hypothalamic neurotransmitters
C. Arévalo (2001)
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase
B. Cravatt (2001)
Sex differences in antinociceptive and motoric effects of cannabinoids.
A. H. Tseng (2001)
Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal.
F. Rodríguez de Fonseca (1997)
Structural determinants for recognition and translocation by the anandamide transporter.
D. Piomelli (1999)
The influence of 5-hydroxytryptamine re-uptake blockade on CCK receptor antagonist effects in the rat elevated zero-maze.
M. J. Bickerdike (1994)
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum
A. Giuffrida (1999)
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain.
T. Sugiura (1995)
Rat pup ultrasonic isolation calls: Possible mediation by the benzodiazepine receptor complex
T. Insel (1986)
Localization of the CB1 type cannabinoid receptor in the rat basolateral amygdala: high concentrations in a subpopulation of cholecystokinin-containing interneurons
A. McDonald (2001)
Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides
B. Cravatt (1996)
Therapeutic aspects of cannabis and cannabinoids.
P. Robson (2001)

This paper is referenced by
Acute hypertension reveals depressor and vasodilator effects of cannabinoids in conscious rats
W. Ho (2009)
The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear‐conditioned analgesia and controls fear expression in the presence of nociceptive tone
W. Olango (2012)
Identification of a Novel Endocannabinoid-Hydrolyzing Enzyme Expressed by Microglial Cells
G. Muccioli (2007)
The endogenous cannabinoid system and drug addiction: 20 years after the discovery of the CB1 receptor
F. Rodríguez de Fonseca (2008)
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling
Adrián Bartoll (2020)
Cannabinoids and Reproduction: A Lasting and Intriguing History
G. Cacciola (2010)
Examination of the Neuroprotective Effects of URB597 in Young and Aged Rat Retina
Joanna E. Slusar (2010)
Potential Therapeutic Value of a Novel FAAH Inhibitor for the Treatment of Anxiety
E. M. Marco (2015)
Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor
D. Kerr (2012)
Differences in Spontaneously Avoiding or Approaching Mice Reflect Differences in CB1-Mediated Signaling of Dorsal Striatal Transmission
Daniela Laricchiuta (2012)
Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB1 and CB2 receptors
J. Desroches (2014)
Cannabinoid receptor stimulation increases motivation for nicotine and nicotine seeking
I. Gamaleddin (2012)
A review from patents inspired by the genus Cannabis
I. J. Flores-Sánchez (2016)
An endocannabinoid mechanism for stress-induced analgesia
A. Hohmann (2005)
The role of the endocannabinoid system in fertility control
T. Karasu (2013)
Investigating the role of the endogenous cannabinoid system in emotional modulation of pain: neurochemical and molecular mechanisms
W. Olango (2012)
Involvement of endocannabinoids in antidepressant and anti-compulsive effect of fluoxetine in mice
S. Umathe (2011)
A FAAH-regulated class of N-acyl taurines that activates TRP ion channels.
A. Saghatelian (2006)
SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance
Cristiano Nazzaro (2012)
Effects of TRPV1 Activation by Capsaicin and Endogenous N-Arachidonoyl Taurine on Synaptic Transmission in the Prefrontal Cortex
Mingyue Zhang (2020)
Opposite control of frontocortical 2‐arachidonoylglycerol turnover rate by cannabinoid type‐1 receptors located on glutamatergic neurons and on astrocytes
Ilaria Belluomo (2015)
Endocannabinoid signaling in microglial cells
N. Stella (2009)
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.
Jeannie Hwang (2010)
Serum endocannabinoid content is altered in females with depressive disorders: a preliminary report.
M. Hill (2008)
The neurobiology of individual differences in complex behavioral traits.
A. Hariri (2009)
Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain
M. Jhaveri (2007)
Brain permeant and impermeant inhibitors of fatty‐acid amide hydrolase suppress the development and maintenance of paclitaxel‐induced neuropathic pain without producing tolerance or physical dependence in vivo and synergize with paclitaxel to reduce tumor cell line viability in vitro
Richard A. Slivicki (2019)
Cat odour-induced anxiety—a study of the involvement of the endocannabinoid system
S. Sütt (2007)
Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor
J. ConnorT. (2019)
Characterization of the fatty-acid amide hydrolase inhibitor URB 597 : Effects on anandamide and oleoylethanolamide deactivation
D. Fegley (2004)
A. Li (2010)
Omega-3 polyunsaturated fatty acids and their impact upon the biosynthesis of endocannabinoids and N-acylethanolamines in human skin cells in the presence and absence of ultraviolet radiation
Abdalla F M Almaedani (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar